What You're Actually Asking For
If you've been told to "request a formulary exception" for Keytruda, or you searched that phrase because your oncologist's office used it, here's the thing worth knowing before you fill out any paperwork: the term itself is borrowed from a part of Medicare that Keytruda doesn't live in. That doesn't mean you're stuck — it means the actual mechanism you need has a different name, and using the right one will get your request routed correctly the first time instead of bouncing back for resubmission.
This guide exists because most explanations of "formulary exceptions" online are written generically for Part D pharmacy drugs — the kind you pick up at a retail counter — and then get applied wholesale to a drug like Keytruda, which almost nobody picks up at a pharmacy at all. We're going to walk through what's actually happening when a plan won't cover Keytruda or Keytruda Qlex the way your doctor prescribed it, using real 2026 payer policy language rather than a generic template.
Why "Formulary Exception" Is the Wrong Word — And Why It Sticks Anyway
By CMS's own definition, a formulary exception is a request to a Medicare Part D plan sponsor to cover a drug that isn't on its formulary, or to waive a utilization management requirement — like step therapy — on a formulary drug. It's specifically a Part D mechanism. Keytruda and Keytruda Qlex are infused or injected by a healthcare provider, which means they're billed under Medicare Part B (the medical benefit) or, for commercially insured patients, a plan's medical or specialty pharmacy benefit — not Part D. For the full explanation of why that billing distinction exists and what it means for your out-of-pocket cost, see our Keytruda cost guide.
So why does everyone, including insurers themselves, keep calling it a "formulary exception" anyway? Because the underlying idea — asking a payer to cover something outside its preferred list — is functionally identical, and a lot of plan paperwork simply reuses the familiar phrase. A real 2026 oncology prior authorization form we reviewed literally asks providers for the "rationale for drug formulary or step-therapy exception request" on a single line, treating the two as one category. In practice, insurers, patient advocates, and even some plan documents use "formulary exception," "non-formulary exception," and "step therapy exception" as loose synonyms for medical-benefit drugs like Keytruda, even though only the last one is technically accurate.
The Three Real Scenarios Behind This Search
Depending on your coverage, "formulary exception for Keytruda" maps to one of three genuinely different processes. Knowing which one applies to you changes who you contact and what form you use.
| Your Coverage | What It's Actually Called | Who Grants It |
|---|---|---|
| Medicare Advantage (with or without Part D) | Part B step therapy exception | Your Medicare Advantage plan directly |
| Commercial or employer-sponsored insurance | Non-preferred / medical necessity exception, sometimes still labeled "formulary exception" on plan forms | Your insurer's medical or pharmacy benefit manager, depending on how the drug is billed |
| Medicaid (state or managed care) | Prior authorization override on the state's preferred drug list (PDL) | Your state Medicaid agency or your Medicaid MCO |
Original Medicare without a Medicare Advantage plan doesn't use a preferred/non-preferred structure for Part B drugs at all, so this specific issue mostly doesn't arise there — Keytruda is either a covered, medically necessary Part B drug for your diagnosis or it isn't, a distinction we cover in detail in our Keytruda prior authorization guide. If you're on Medicaid, the mandatory-coverage mechanics behind why Keytruda is on your state's formulary at all are covered in our Keytruda savings card guide and its companion pricing coverage.
Real Example: Preferred for One Cancer, Non-Preferred for Another
Here's the part that catches people off guard, and it's not a hypothetical — it's drawn directly from a 2026 Medicare Advantage Part B step therapy program document. On the same plan, in the same program, Keytruda's status changes depending on what it's being used to treat:
| Cancer Type / Class | Keytruda's Status | What That Means |
|---|---|---|
| Non-small cell lung cancer (NSCLC), PD-L1 monotherapy | Preferred | No step therapy exception needed |
| Nasopharyngeal carcinoma | Non-preferred | Plan requires trial or documented issue with the preferred agent first, unless an exception is granted |
This is the single biggest thing a generic "how to request a formulary exception" article will never tell you: whether you need to file anything at all depends on your specific diagnosis, not on Keytruda's overall reputation as a standard-of-care checkpoint inhibitor. The same plan can wave a lung cancer patient straight through while requiring a nasopharyngeal cancer patient to document a trial of a different, preferred PD-1/PD-L1 inhibitor first — or to request an exception explaining why that isn't appropriate. Insurers also don't necessarily agree with each other: one plan's 2026 preferred drug list may name Keytruda as the preferred checkpoint inhibitor for a given cancer type, while a different Medicare Advantage insurer's list for the same class names a different product as preferred instead. There's no substitute for checking your specific plan's current Part B step therapy or oncology drug policy for your specific diagnosis before assuming either way.
The Keytruda Qlex Wrinkle
Keytruda Qlex — the subcutaneous injection version, given in as little as one to two minutes compared with the roughly 30-minute IV infusion — was FDA-approved in September 2025 with its own billing code, separate from standard IV Keytruda. Because it's legally and administratively a distinct product, it hasn't simply inherited every existing Keytruda coverage policy automatically, and by mid-2026 some payers had built specific criteria around it.
A real, dated example: One health plan's May 2026 formulary update log shows Keytruda Qlex being added to its policy with an explicit note: "Added step criteria for Keytruda Qlex to step through Keytruda." In plain terms — a patient generally needs to be established on IV Keytruda first before that plan will approve Qlex, rather than allowing a new patient to start directly on the subcutaneous version. A separate commercial insurer's clinical policy bulletin similarly addresses Keytruda and Keytruda Qlex together but lists exclusion criteria specific to Qlex, including certain pediatric tumor types.
What this means practically: if your oncologist wants to start you on Qlex from day one — for the shorter chair time, for instance — or wants to switch you from IV Keytruda to Qlex mid-treatment, it's worth confirming with your specific plan whether that requires its own authorization or exception request, separate from whatever coverage decision already exists for IV Keytruda. Don't assume an existing Keytruda approval automatically covers Qlex, and don't assume the reverse either.
What Actually Belongs in the Exception Request
Every exception request — whether it's technically a Part B step therapy exception, a commercial non-preferred exception, or a Medicaid PDL override — succeeds or fails on the same core question: does the prescriber's supporting statement address a specific, recognized override ground, or does it just assert medical necessity in general terms? Based on CMS's own model exceptions language and the override grounds written into multiple state step therapy statutes, the grounds that actually move a request forward are:
- The preferred drug has already been tried and failed — with dates, doses, and documented outcome, not just "prior therapy attempted."
- The preferred drug is contraindicated or is expected to cause an adverse reaction based on the patient's documented history or comorbidities.
- The preferred drug is expected to be less effective for this patient's specific tumor type, staging, or biomarker status (for example, PD-L1 expression level or MSI-H/dMMR status) — supported by chart notes or test results, not just a general clinical impression.
- The patient is already clinically stable on Keytruda or Keytruda Qlex, and switching poses a documented risk of disease progression or adverse outcome.
What tends to stall a request: a supporting letter that states Keytruda is "medically necessary" without directly addressing why the plan's specific preferred alternative for that diagnosis won't work. Reviewers — often including board-certified oncologists on the payer side — are evaluating the request against one of the grounds above, not against a general endorsement of Keytruda as a good drug.
How Fast Should You Get an Answer?
Response timeframes differ by coverage type, but they cluster around the same two numbers across nearly every source we reviewed: 72 hours for a standard request, 24 hours for an expedited request when a delay could seriously jeopardize your health.
| Coverage Type | Standard Response | Expedited Response |
|---|---|---|
| Medicare Advantage (Part B step therapy exception) | As expeditiously as your condition requires, generally within 72 hours | Available on request when clinically urgent |
| Commercial insurance (state-regulated plans, most states) | 72 hours | 24 hours for exigent circumstances |
| Self-funded employer (ERISA) plans | Set by the plan itself — not bound by state deadlines | Varies by plan; ask your benefits administrator |
A related, newer detail worth knowing: CMS's interoperability and prior authorization rule set a general standard for Medicare Advantage plans of a 7-calendar-day response window for standard prior authorization decisions and 72 hours for expedited ones, effective for determinations made in 2026 — a slightly different framing than the "as expeditiously as required" language used specifically for Part B step therapy exceptions, but pointed at the same goal of limiting how long a plan can sit on a decision.
State Step Therapy Laws — and the ERISA Gap
More than 30 states have passed some form of step therapy override or reform law covering commercial insurance, generally requiring insurers to offer a clear exception process with defined response deadlines, and to grant an override when specific circumstances apply — most commonly: the required drug was already tried and failed, is contraindicated, is expected to be ineffective, isn't in the patient's best interest, or the patient is already stable on their current medication. Several of these laws go further and state that if the insurer misses its own deadline, the request is automatically deemed approved.
The gap most people don't know about: these state laws generally apply to state-regulated insurance — individual plans, small group plans, and fully insured employer plans. Self-funded employer plans, which are common at larger companies, are regulated under the federal ERISA law instead and are typically exempt from state step therapy override requirements. If your coverage comes through a large employer, you may not have the same statutory deadline or automatic-approval protection your state's law otherwise provides — though your plan may still voluntarily offer a similar process. Your plan's Summary Plan Description, or a call to your HR benefits team, will tell you whether your plan is fully insured or self-funded.
Fewer states extend these override protections to their Medicaid programs specifically — most step therapy reform laws were written with commercial insurance in mind, so Medicaid step therapy exception rules more often come from state agency regulation rather than the same statute covering private plans, even within the same state.
If the Exception Is Denied
A denial isn't the end of the process — it's the start of an appeal, and the path differs by coverage type.
Read the denial letter for its stated reason
The specific reason cited determines what your appeal needs to address — a denial for "insufficient clinical documentation" needs different evidence than one for "does not meet plan criteria for this diagnosis."
File an internal appeal within the stated deadline
Medicare Advantage appeals (redeterminations) and commercial internal appeals both have specific filing windows stated in your denial letter — don't let this lapse while gathering documentation.
Request an expedited appeal if treatment delay is a clinical concern
Both Medicare Advantage and most state-regulated commercial plans offer an expedited appeal track when a standard timeline could cause harm — ask your oncology office to specifically request this rather than assuming it's automatic.
Escalate to external review if the internal appeal is denied
For Medicare Advantage, this means Medicare's multi-level appeals process. For most state-regulated commercial plans, it means an independent external review through your state's process, which is not run by your insurer. Self-funded ERISA plans have their own internal appeals procedure but more limited external review rights, so it's worth asking your plan administrator directly what your options are.
For a deeper walkthrough of the prior authorization side of this — including what documentation oncology offices typically submit up front to avoid a denial in the first place — see our Keytruda prior authorization guide.
Formulary vs. Tiering vs. Step Therapy vs. Prior Authorization
These four terms get used almost interchangeably in casual conversation, but they're distinct tools, and knowing which one actually applies to Keytruda saves you from filling out the wrong form.
| Term | What It Actually Does | Applies to Keytruda? |
|---|---|---|
| Formulary exception (Part D) | Adds a non-formulary retail pharmacy drug to coverage | Rarely — Keytruda isn't a Part D drug |
| Tiering exception | Moves a covered drug to a lower-cost tier | No — Keytruda isn't tiered the way oral pharmacy drugs are |
| Step therapy exception | Skips a required "try the preferred drug first" step | Yes — this is usually the actual mechanism in play |
| Prior authorization | Confirms medical necessity before the plan will pay at all | Yes — usually required regardless of preferred status |
Which Request Applies to You?
What kind of coverage do you have?
This determines which process and which deadline apply
Is Keytruda "non-preferred" for your specific diagnosis?
Check the plan's current Part B step therapy drug list
File a Part B step therapy exception
Supporting statement should address a specific override ground
Fully insured, self-funded, or Medicaid?
This determines whether state step therapy law protections apply
File a non-preferred / medical necessity exception
Use your state's exception form if one exists for your plan type
Considering Keytruda Qlex specifically?
Confirm whether your plan requires a separate authorization or a step-through from IV Keytruda first
Common Mistakes
- Searching for and trying to use a Part D formulary exception process for Keytruda, which isn't a Part D drug in the first place.
- Assuming Keytruda's preferred status is the same across every cancer type on your plan — it isn't, and the difference matters.
- Submitting a generic "medically necessary" letter instead of one that addresses a specific override ground with dates and documentation.
- Assuming an existing IV Keytruda approval automatically covers Keytruda Qlex, or vice versa.
- Not checking whether your employer plan is self-funded before relying on your state's step therapy override deadlines.
- Missing the internal appeal filing deadline while still gathering documentation for a denial.
Quick Checklist Before You Submit
| Checklist Item | Status |
|---|---|
| Confirmed whether your coverage is Medicare Advantage, commercial, or Medicaid | ☐ |
| Checked your plan's current Part B step therapy or oncology drug policy for your specific diagnosis | ☐ |
| Confirmed whether your employer plan is fully insured or self-funded (ERISA) | ☐ |
| Supporting statement addresses a specific override ground, not just general medical necessity | ☐ |
| Requested expedited review if a delay could seriously affect your treatment timeline | ☐ |
| If requesting Keytruda Qlex specifically, confirmed whether a step-through from IV Keytruda is required | ☐ |
| Noted the response deadline and calendar-flagged a follow-up if you haven't heard back | ☐ |
Bottom Line
A "formulary exception for Keytruda" isn't really a formulary exception at all — it's almost always a step therapy exception or a medical necessity exception on the medical benefit side of your coverage, and which one applies depends on your specific plan and, just as importantly, your specific diagnosis. Keytruda can sail through as the preferred checkpoint inhibitor for one cancer type and require a documented exception for another, on the very same plan. If Keytruda Qlex is part of the conversation, check separately whether your plan treats it as its own coverage decision rather than an automatic extension of an existing Keytruda approval. Your oncology practice's prior authorization team handles this routinely — ask them directly which specific process applies to your plan before assuming.